Prof. Shouping Xu 许守平
Chief Physician, Professor
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical, chemotherapy, and endocrine treatment for benign and malignant breast diseases. Focuses on postoperative management, follow-up support, rehabilitation counseling, tumor diagnosis, standardized treatment, and prevention.
Dr. Xu holds an MD and completed postdoctoral training. Serves as Administrative Director of Ward I, Department of Breast Surgery, Harbin Medical University Cancer Hospital. Also a doctoral supervisor, researcher, chief physician, and professor. Presided over three National Natural Science Foundation projects.
Professional roles
- Member, Chinese Medical Association
- Youth Committee Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Heilongjiang Provincial Breast Cancer Professional Committee
- Youth Committee Member, Tumor Branch, Chinese Medical Association
Name order: in Chinese the family name comes first (Xu Shouping). Papers usually list the name as Shouping Xu or Xu S.
Selected publications
74 papers on PubMed matched by name and affiliation; 26 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancers (Basel), 2026 (senior author): Clinicopathological Characteristics, Prognosis, and Survival of HER2-Low Breast Cancer Patients Based on a Retrospective Cohort Study of 14,642 Patients. PubMed 42192995
- Research (Wash D C), 2026 (senior author): Integrated Proteogenomic Characterization Identifies Breast Cancer Immune Subgroups and Subtype-Specific Therapeutic Strategies. PubMed 42131586
- Adv Sci (Weinh), 2026 (first author): Proteogenomic Characterization Reveals Subtype-Specific Therapeutic Potential for HER2-Low Breast Cancer. PubMed 41454718
- Front Oncol, 2025 (senior author): Higher baseline platelet and preoperative platelets to lymphocytes ratio was associated with a higher incidence of axillary node pathologic complete response after neoadjuvant chemotherapy in HER2-low breast cancer: a retrospective cohort study. PubMed 40161379
- Adv Mater, 2025 (senior author): Tumor-Specific Protein Induced in Situ Self-Assembly of Peptide Drugs for Synergistic Mitochondria Disruption. PubMed 39604290
- J Exp Clin Cancer Res, 2024 (senior author): NAT10/ac4C/JunB facilitates TNBC malignant progression and immunosuppression by driving glycolysis addiction. PubMed 39363363
- Crit Rev Oncol Hematol, 2023 (senior author): Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory. PubMed 37898477
- Cell Death Dis, 2023 (senior author): LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1-TINCR-USP20-PD-L1 axis. PubMed 36725842
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion